Combined Detection of Serum IL-10, IL-17, and CXCL10 Predicts Acute Rejection Following Adult Liver Transplantation.

Discovery of non-invasive diagnostic and predictive biomarkers for acute rejection in liver transplant patients would help to ensure the preservation of liver function in the graft, eventually contributing to improved graft and patient survival. We evaluated selected cytokines and chemokines in the sera from liver transplant patients as potential biomarkers for acute rejection, and found that the combined detection of IL-10, IL-17, and CXCL10 at 1-2 weeks post-operation could predict acute rejection following adult liver transplantation with 97% specificity and 94% sensitivity.

INTRODUCTION

Liver transplantation is often the only option for otherwise non-treatable chronic and acute liver failure. Although the development of immunosuppressive regimens and surgical techniques in last few decades has tremendously improved graft and patient survival, acute rejection still causes serious problems in 10–20% of liver transplant (LT) patients (Song et al., 2014). Standard diagnosis includes liver biopsy, which itself is a highly risky procedure. Hence, there is an urgent need for noninvasive predictive and diagnostic biomarkers to detect acute rejection following LT. As acute rejection is a result of cellular immune responses, circulating cytokines and chemokines could serve as useful predictive or diagnostic biomarkers for acute rejection in LT patients. In particular, cytokines and chemokines that are involved in inflammation and T cell function could be potential biomarkers, as acute rejection is a T cell-mediated process.

Many cytokines and chemokines have been investigated as potential biomarkers for the diagnosis of graft rejection or dysfunction following liver transplantation. Microarray analysis has shown that interleukin (IL)-3, tumor necrosis factor-alpha (TNF-α), and IL-10 mRNAs are increased in biopsy samples from LT patients that show acute rejection (Tannapfel et al., 2001). Another study demonstrated that IL-2 and TNF-α mRNAs were upregulated in biopsy samples collected at day 21 postoperation (PO) from LT patients with acute rejection (Sreekumar et al., 2002). These genes were the only cytokines found to be differentially expressed among several genes analyzed in each study. IL-2, IL-4, and IL-15 mRNAs increased in peripheral blood mononuclear cells from renal allograft patients in the pre-rejection phase (Lee et al., 2012). In a rat liver allograft model, inhibition of IL-4 by mycophenolate was suggested to inhibit rejection (Huang et al., 2003). Serum interferongamma (IFN-γ) peri-operationally, and IL-10 and CXCL10 on days 1 and 2 PO were suggested as biomarkers for early allograft dysfunction after liver transplantation (Karakhanova et al., 2016). IL-17 and IL-23 increased in the sera of patients with rejection on days 1 and 7 PO (Fabrega et al., 2009). Intracellular IFN-γ and IL-2 levels significantly changed in LT patients with acute rejection at 1 week PO, although soluble IL-2 levels were not affected (Millan et al., 2013). Soluble IL-17 in the supernatant after 48 h culture of whole blood cells with concanavalin A and the percentages of IFN-γ+ CD4+CD69+ and IFN-γ+ CD8+CD69+ cells are considered predictive biomarkers of acute rejection in the 2nd and 4th weeks PO (Millan et al., 2014). Although IL-6 is considered to be involved in rejection in lung transplantation (Nakagiri et al., 2012), pre-operational IL-6 levels are lower in LT patients with early allograft dysfunction (Friedman et al., 2012).

CXCR3 ligands have been suggested as candidates for the early diagnosis of acute rejection in various organs such as the kidney, liver, and heart. CXCR3 is expressed on activated T cells and natural killer cells, and its ligands are CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-Tac) (Capece and Kim, 2016). A long-term follow-up study of LT patients for up to 7 years suggested CXCL10 as a biomarker to predict fibrosis in the first year after LT for hepatitis C infection, whereas CXCL11 was less useful (Berres et al., 2011). Serum CXCL9 and CXCL10 levels were found to be significantly higher in LT patients with early allograft dysfunction on day 1 PO, but not after that (Friedman et al., 2012). A recent report suggested that reduced CD44 and increased CXCL9 at day 1 PO could be noninvasive biomarkers in the sera from LT patients with rejection (Raschzok et al., 2015).

Despite these previous efforts, there are no reliable candidate biomarkers for clinical application. In addition, expression of cytokines and chemokines is influenced by several factors such as infections and autoimmune diseases. Hence, the combination of diagnostic and predictive biomarkers could improve the sensitivity and specificity of biomarkers. Accordingly, the aim of this study was to investigate serum levels of selected cytokines and chemokines weekly for one month after adult liver transplantation to evaluate the possibility of using a combination of diagnostic and predictive biomarkers.

MATERIALS AND METHODS

Patients

From February 2012 to July 2012, adult patients undergoing LT surgery at Asan Medical Center, Seoul, Korea were prospectively enrolled in this study. The study was approved by the Institutional Review Board (Approval No. 2011-0898) and written informed consent was obtained from all participants. All patients were provided with standard care and treatment. The demographic and clinical characteristics of the patients are shown in Table 1.

Table 1.

Demographic and clinical characteristics of liver transplant patients

	Control	Rejection
Gender	M 27, F 8	M 13, F 4
Age (years)	51 ± 1.191	48 ± 2.008
Type of operation	LD 31, CD 3, dual 1	LD 15, CD 1, dual 2
ABO compatibility	C 27, I 8	C 14, I 3
Original diseases	LC (HBV) 26	LC (HBV) 6
	LC (HBV, alcohol) 1	LC (HCV) 2
	LC (NBNC) 1	PSC 1
	ALC LC 4	HCC 1
	SBC 1	ALC LC 3
	Retransplant 2	Toxic hepatitis-FHF 1Fulminant hepatitis (r/o HAV AH) 1Retransplant 2
Days to rejection		18 ± 7.295
Cold ischemic time	83.5 ± 11.564	96 ± 16.262
Warm ischemic time	38 ± 2.718	38 ± 3.572
Total ischemic time	124 ± 12.322	136 ± 18.036
MELD score	12 ± 1.799	15.5 ± 1.743

AH, acute hepatitis; ALC, alcoholic; C, compatible; CD, cadaveric donor; dual, dual transplantation; FHF, fulminant hepatic failure; HAV, hepatitis A virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; I, incompatible; LC, liver cirrhosis; LD, living donor; NBNC, non-HBV and non-HCV; PSC, primary sclerosing cholangititis; SBC, secondary biliary cirrhosis

Serum collection and selection

Whole blood from LT recipients at LT wards, not at the intensive care unit or outpatient clinics, was collected in STT BD Vacutainer tubes (BD, USA) weekly for 4 weeks PO, and sera were harvested within 2 h and stored in a deep freezer until use. Six months later, the patients were classified into acute rejection and control (no rejection) groups by reviewing medical records. A clinical diagnosis of acute rejection was considered when alanine aminotransferase (ALT) and bilirubin levels rose without evidence of infections, thrombosis, and other complications. Biopsy confirmed the results; in some cases, the patients were immediately treated with standard rejection therapeutics without biopsy, which was considered as clinical rejection. Patients without rejection of similar ages and gender were selected as the control group. Among the 164 patients enrolled, 17 patients with rejection and 35 controls were selected; however, given that it was not possible to collect samples in a timely manner for all the patients at the designated dates, the sample numbers vary at each time point. None of the patients had other complications or infections at one month PO.

Multiplex chemokine assay

A multiplex chemokine assay to assess serum concentration of IL-2, IL-4, IL-6, TNF-α, IFN-γ, IL-10, IL-17A, CXCL9, CXCL10, and CXCL11 was performed using a Cytometric Bead Array system (BD Biosciences, USA) following the manufacturer instructions. The results were analyzed with FACScanto II (BD Biosciences) and FCAP Array multiplex analysis software (BD Biosciences).

Statistical analysis

Medians and standard errors of the means were calculated with GraphPad InStat 3 (Version 3.10) software (GraphPad, Inc., USA). Two-tailed Student t tests were performed with Excel software (Microsoft, Co., USA). Receiver operating characteristic (ROC) curve analysis was performed to estimate the potential predictive or prognostic value of the parameters investigated using area under the curve (AUC) estimation with SPSS software (SPSS, Inc., USA). Multivariate analysis and logistic regression analysis were also performed using SPSS software. Missing data were not replaced or imputed. A value of P < 0.05 was considered statistically significant.

RESULTS

Patients with rejection and those without rejection (control group) were similar in age, gender, and types of operation (Table 1). As common in Korea, the majority of transplants were from living donors (over 85% in both groups). All the donors and recipients were of Korean ethnicity. ABO-incompatible donors accounted for approximately 25% and 20% of all living donors in the control group and rejection group, respectively. All patients were given calcineurin inhibitors (approximately 90% and 85% tacrolimus and 10% and 15% cyclosporin A in the control and rejection groups, respectively) as a part of standard immunosuppressant regimens. There were no significant differences in cold, warm, and total ischemic times or in model of end-stage liver disease (MELD) scores between the two groups. The MELD score comprises serum creatine and serum bilirubin levels, and the international normalized ratio for prothrombin time measurement. The median days from operation to a diagnosis of rejection, or to the date of starting rejection therapy in the case of clinical rejection, was 18. Seven of the 17 total rejection patients showed clinical rejection.

Liver function was regularly checked using several tests, including measurement of the serum ALT level, which is an important parameter to diagnose rejection. As shown in Fig. 1, ALT concentrations were significantly higher in the rejection group from the 2nd to 4th week PO compared to those of the control group. As acute rejection was diagnosed and treated at an average of 18 days PO (Table 1), serum ALT levels tended to decrease slightly at 4 weeks PO.

Fig. 1.

Serum ALT levels in LT patients with or without acute rejection. Data represent the median + SEM. *p < 0.05; ** p < 0.01; *** p < 0.001.

Serum IL-10 and IL-17 levels increased at 1–2 weeks PO

Several cytokines were measured in the sera from LT patients. We focused specifically on IL-2, IL-4, IL-6, TNF-α, IFN-γ, IL-10, and IL-17A, as they are known to be involved in inflammation, T cell survival and homeostasis, and in the regulation of various effector functions of T cells such as Th1, Th2, regulatory T cells, and Th17. Importantly, all of these cytokines have been shown to be involved in allogeneic immune responses or suggested as biomarkers for rejection. Notably, serum IL-17 concentrations were significantly higher in the rejection patients at 1 week PO (Fig. 2), but decreased after that point. IL-10 levels were significantly higher in the rejection group at 2–3 weeks PO. IL-2 and IL-4 appeared to be increased in the rejection group, but the individual variation was very large. IL-6 and TNF-α levels were too low to detect in many samples. IFN-γ levels appeared to be dynamic and showed high variation. These results suggested that detection of serum IL-10 and IL-17 at proper time points could help to predict the potential for acute rejection.

Fig. 2.

Serum cytokine levels in LT patients with or without acute rejection. Data represent median + SEM. N = 20, 21, 16, and 7 in the control group; N = 13, 16, 15, and 10 in the rejection group at week 1, 2, 3, and 4, respectively. *p < 0.05; **p < 0.01.

Serum CXCL10 and CXCL11 levels increased at 2-3 weeks PO

CXCR3 ligands were selected for further evaluation, as they have been suggested as biomarkers for graft rejection or dysfunction by many researchers. As shown in Fig. 3, serum CXCL10 and CXCL11 concentrations were significantly increased in the rejection group, whereas CXCL9 concentrations were not. CXCL10 levels increased consistently in the rejection group, and at the 3rd week, the difference was statistically significant. Interestingly, CXCL11 levels dramatically increased from 1 week PO onward. Therefore, CXCL10 and CXCL11 could be diagnostic biomarkers.

Fig. 3.

Serum CXCR3 ligand levels in LT patients with or without acute rejection. Data represent median + SEM. N = 20, 21, 16, and 7 in the control group; N = 13, 16, 15, and 10 in the rejection group at week 1, 2, 3, and 4, respectively. *p < 0.05; **p < 0.01.

Combined detection of IL-10, IL-17, and CXCL10 has strong predictive power

To verify the potential for the combined use of IL-10, IL-17, CXCL10, and CXCL11 as diagnostic or predictive biomarkers, multivariate logistic regression analysis was performed (Fig. 4 and Table 2). The strongest predictive power was achieved when IL-17 and CXCL10 were assessed at week 1 PO and when IL-10 was assessed at week 2. The sensitivities of IL-17, IL-10, and CXCL10 were 75%, 81%, and 78%, and the specificities were 70%, 75%, and 77%, respectively. Multivariate modeling showed that the sensitivity of all three markers together was 94% and the specificity was 97% with an AUC value of 0.949. Unexpectedly, CXCL10 measured at week 1 PO was a better predictive biomarker than CXCL11 measured at week 2 in combination, although the difference in CXCL10 levels between the control and rejection groups was not statistically significant at week 1. These results demonstrated that serum levels of IL-10, IL-17, and CXCL10 measured at weeks 1 and 2 in combination can predict acute rejection in adult LT patients earlier than diagnosis with conventional methods.

Fig. 4.

Predicting the capacity for acute rejection. Receiver operating characteristic (ROC) curve analysis was performed to define the area under the curve (AUC), sensitivity, and specificity for IL-10 at week 2, IL-17 at week 1, and CXCL10 at week 1 PO. (A) Predictive capacity of each parameter. (B) Multivariate analysis of IL-10, IL-17, and CXCL10.

Table 2.

Summary of the predictive capacity for acute rejection

	IL-17 (1 week PO)	IL-10 (2 weeks PO)	CXCL10 (1 week PO)	Multivariate modeling
AUC	0.750	0.729	0.752	0.949
Sensitivity	75	81	78	94
Specificity	70	75	77	97
Cut-off values	24.56	18.31	217.00

AUC, area under the curve; PO, post-operation

DISCUSSION

In this study, we suggest the detection of IL-10, IL-17, and CXCL10 in combination as non-invasive predictive biomarkers for acute rejection in LT patients. There was no significant difference in the demographic characteristics of LT patients with and without acute rejection, in any of the parameters compared. This study also supports the results of our previous work showing that ABO incompatibility does not contribute to a higher risk of acute rejection (Song et al., 2014), as the rejection group did not include more patients receiving ABO-incompatible LT.

These results are in line with previous reports demonstrating that IL-17 was increased in the sera from LT patients showing rejection at days 1 and 7 PO (Fabrega et al., 2009). Intracellular IFN-γ in activated T cells was previously shown to increase at 2–4 weeks PO (Millan et al., 2014), whereas IFN-γ was not significantly different in the sera of LT patients with and without rejection at same time points in the present study. IL-10 was significantly upregulated in the rejection group in our study. At the time of onset of acute rejection, Th17 cells are significantly higher in the blood of LT patients with acute rejection, while circulating regulatory T cells are decreased (Wang et al., 2014). However, a high frequency of central memory regulatory T cells was detected in LT patients at risk of early acute rejection within the 1st month PO (Boix-Giner et al., 2016). This suggests that the increase in central memory regulatory T cells, rather than naïve regulatory T cells, may have produced the increased IL-10 found in this study. In addition, increased Th17 cells and secreted IL-17 may play an important role in acute rejection. Indeed, neutralization of IL-17 with an antibody significantly prolonged liver graft survival in rats (Zhou et al., 2015). Notably, increased IL-10 also indicates a high risk for late cytomegalovi rus disease (Krishnan et al., 2010). The present study did not include LT patients with infection; therefore, comparison of serum cytokines and chemokines between LT patients with rejection and with infection may provide more specific differential diagnostic and predictive biomarkers.

IL-2 and IL-4 levels in the sera from the rejection group were slightly higher than those of the control, although these differences were not statistically significant. This weak effect might be related to the relatively small sample size, and therefore a larger cohort study may clarify this issue. Furthermore, IL-6 and TNF-α levels were very low, likely below the detection limits of the assays. One potential reason for the discrepancy in results among studies might be different techniques and affinities of antibodies used to target specific proteins. For example, multiplex cytokine assays are known to be less sensitive than enzyme-linked immunoassays. In addition, the Luminex and Cytometric Bead Array systems have different sensitivities in our experience. Moreover, etiological factors might influence these results. Liver cirrhosis after hepatitis B virus (HBV) infection is prevalent in Korea, which is not the case in Western countries where most previous studies have been conducted. At the time of transplantation, HBV virus titers should be below detectable levels, but the host immune system might be biased in cases of chronic infection. In addition, the majority of LT surgeries in Korea involve living donors, which are usually associated with a lower ischemic time. Thus, ischemia reperfusion injury and consequent inflammation could be milder in Korean LT patients.

Serum CXCL10 and CXCL11 appear to be more potent biomarkers than CXCL9 for acute rejection in LT, according to the results of the present study. However, CXCL11 has been relatively less investigated than CXCL9 and CXCL10 in previous studies. Serum CXCL9 and CXCL10 were found to be significantly higher in LT patients with early allograft dysfunction on day 1 PO, but not subsequently (Friedman et al., 2012). The main cause of early allograft dysfunction is thought to be ischemia reperfusion injury, whereas the current study focused on acute rejection, which occurs later than ischemia reperfusion injury. CXCR3 is expressed in activated T cells, which plays a main role in acute cellular rejection. Therefore, increased CXCR3 ligands could promote activated T cell migration and rejection. CXCR3 and IL-10 were found to be down-regulated in the proliferative phase during liver regeneration in rats (Xu et al., 2011), suggesting that up-regulated CXCR ligands and IL-10 might have regulatory roles in liver regeneration, thereby delaying graft accommodation.

As IL-17 was found to be up-regulated at 1 week PO, it might be interesting to assess CCL20, a CCR6 ligand, which plays a key role in the migration of Th17 cells (Kim, 2009). A previous report showed that liver graft strongly upregulated CCL20 within 1 h after ischemia reperfusion injury (Ingelsten et al., 2011). In addition, loss of HERC5 expression in patients with recurrent hepatocellular carcinoma (HCC) post-LT has been suggested to drive the up-regulation of CCL20 in HCC cells (Xue et al., 2015). It should be noted that ischemic times were not different between the rejection and control groups in our study, and transplant patients with HCC are relatively rare in Korea. To our knowledge, CCL20 has not been suggested as a biomarker for graft rejection, but it would be interesting to evaluate its potential value.

As mentioned above, some cytokines and chemokines are involved in not only the rejection process but also in other inflammatory and immunological events; hence, it would be useful to combine multiple biomarkers to achieve more accurate diagnosis and prediction. Therefore, in this study, multivariate modeling was performed with IL-10, IL-17, CXCL10, and CXCL11 at 1–2 weeks PO. To our surprise, CXCL10 at week 1 PO emerged as a better predictive biomarker than CXCL11 at week 2, implying that the difference in serum CXCL10 levels might actually be statistically significant in a larger cohort. The strongest prediction rate was achieved when IL-10 at 2 weeks PO, and IL-17 and CXCL10 at 1 week PO were combined in the analysis. With these three factors, acute rejection could be predicted in 2 weeks, which is days earlier than the average diagnosis time obtained with conventional methods. Earlier diagnosis could provide a better opportunity to treat rejection and consequently preserve graft function. These candidate biomarkers should also be evaluated at earlier time points such as at 1–7 days PO or even peri-operationally.

In conclusion, the combined detection of serum IL-10, IL-17, and CXCL10 can predict acute rejection following adult liver transplantation. However, the results must be confirmed in larger cohort studies.